Pfizer Partnered With Enodia Therapeutics
The pharmaceutical giant signed a research agreement to develop novel Sec61 inhibitors for various disease targets.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that major pharmaceutical investments in experimental technology will lead to better health outcomes?
Pfizer has entered into a research collaboration and license agreement with Enodia Therapeutics to discover and develop Sec61 inhibitors. The deal grants Pfizer responsibility for clinical development, manufacturing, and commercialization activities.
Why it matters
The companies aim to treat diseases at their source by targeting the Sec61 channel, which prevents disease-driving proteins from reaching the cell surface. This strategic collaboration allows Pfizer to leverage Enodia's platform to potentially address multiple medical targets.
The partnership focuses on Sec61 inhibitors designed to block protein transport pathways. Enodia may receive tiered royalties on net sales in addition to the R&D and commercial milestone payments.
The players
Pfizer
Pfizer is a global pharmaceutical corporation that develops and manufactures a wide range of medical treatments and vaccines.
Enodia Therapeutics
Enodia Therapeutics is a biotech firm specializing in the development of Sec61 inhibitors to prevent disease-driving proteins from exiting the cell.
Kezar
Kezar is a life sciences company that previously entered into an inhibitor licensing arrangement with Enodia.
Eli Lilly
Eli Lilly is a pharmaceutical manufacturer that recently formed an $870 million partnership with Gate Bioscience.
The details
Enodia utilizes a specialized platform to stop protein damage by obstructing the Sec61 channel. Pfizer Ventures previously supported the company during a 20.7 million euro seed investment round in January.
Timeline
January 2026: Pfizer Ventures participated in a 20.7 million euro seed investment in Enodia.
March 2026: Enodia made a $1 million upfront payment to Kezar for an inhibitor.
October 2026: Pfizer and Enodia signed their formal research collaboration agreement.
The Tech Race
This partnership mirrors the recent industry trend of major pharmaceutical firms securing exclusive rights to emerging protein-targeting biotech platforms. The deal positions Pfizer to compete in the high-stakes sector of intracellular therapeutic development against rivals like Eli Lilly.
This collaboration is part of long-term R&D efforts and will not result in immediate changes to drug availability or costs for patients. Successful development of these inhibitors could eventually lead to new treatment options for diseases currently difficult to address with traditional medicine.
The takeaway
The partnership highlights how major pharmaceutical companies are investing heavily in early-stage biotech to secure proprietary protein-blocking technologies. Investors and patients should view this as a long-term research play that remains in the early stages of the clinical pipeline.
Further reading
Learn more about the latest industry developments in biotech.
Live Poll
Do you trust that major pharmaceutical investments in experimental technology will lead to better health outcomes?
